Clinical Study on the Treatment of COVID-19 with Medical Autohemotherapy of ozone

Shanghai East Hospital, Tongji University School of Medicine

ABSTRACT

Condition

COVID-19

Intervention

Ozone treatment groupDrug therapy was carried out according to the guidelines for the diagnosis and treatment of COVID-19+ Ozone autologous blood therapy;Control group Drug therapy was carried out according to the guidelines for the diagnosis and treatment of COVID-19;

Primary

outcome:

Inflammatory marker ;

Criteria

Inclusion criteria Age 18-80, male and female;
The diagnostic criteria for mild and medium novel coronavirus pneumonia in adults in the 10th Trial Edition of the 2023 Diagnosis and treatment plan are1. Have clinical manifestations related to COVID-19 infection; 2. Have one or more of the following etiological and serological test

results:

(1) positive nucleic acid test of novel coronavirus; (2) positive antigen test of novel coronavirus; (3) Isolation and culture of the novel coronavirus are positive; (4) The level of novel coronavirus specific IgG antibody increased 4 times or more in the convalescent phase than in the acute phase. Clinical classification (1) Mild. The main manifestations were respiratory tract infection, such as dry throat, sore throat, cough, fever, etc. (2) medium-sized. Persistent high fever > 3 days or/and/or cough, shortness of breath, but RR < 30 beats/min, oxygen saturation > 93% when breathing at rest. Imaging shows the characteristic manifestations of COVID-19 pneumonia;
Patients who signed informed consent forms.

Exclusion criteria Massive blood loss, acute bleeding, anemia (Hb<90g/L); Severe coagulopathy or thrombocytopenia less than 50X10^9/L; Thalassemia, sickle cell anemia, glucose-6-phosphate dehydrogenase deficiency (patients with faba disease); Toxic diffuse goiter (Graves' disease); Severe unstable cardiovascular disease, acute myocardial infarction; Women who are pregnant or lactating or menstruating in women; Patients with psychiatric, neurological conditions or hypersensitivity; Continuous use of immunosuppressants or organ transplantation within the past 6 months; Investigator-assessed participants who felt that they were unable or unwilling to adhere to the protocol requirements. Intestinal obstruction, intestinal perforation, acute alcohol poisoning.